

Depositions and Court Testimony

Marc B. Garnick, M.D.

Witt v. Buonomono, Connecticut case, Attorney Richard A. O'Connor, trial testimony.

Altshuler v. McCarthy, Massachusetts, Suffolk Superior Case No. SUCV2000-03755, trial testimony

Bhambi v. Piper, Massachusetts, Suffolk Superior Case No. SUCV2000-04189, trial testimony

Kaiser Permanente v. Bresnahan, District of Columbia case, video deposition.

Rubin v. Gold, Florida case, Attorney Paul Buschmann, video deposition.

Curriculum Vitae

Name: Marc Bennett Garnick, M.D.

Hospital Address: Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, Massachusetts 02215
Telephone (hospital pager): 617-667-5555 - ID 33065
Office (appointments): 617-667-5288
Digital Pager: 781-226-5007
e-mail (through pager) 781-226-5007@archwireless.net
mgarnick@bidmc.harvard.edu

Home Address: 140 Dudley Street
Brookline, MA 02445-5908

Date of Birth: January 8, 1947

Place of Birth: Lawrence, Massachusetts

Education:

1968 AB	Bowdoin College, Brunswick, Maine
1972 MD	University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Postdoctoral Training:

Internships and Residencies:

1972-1973	Medical Intern, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
1973-1974	Medical Resident, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Fellowships:

1974-1976	Clinical Associate, Division of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Phoenix, Arizona, and Bethesda, Maryland
1976-1978	Clinical Fellow in Medicine, Harvard Medical School, Boston, Massachusetts
1976-1978	Clinical Fellow in Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Licensure and Certification

1976	Massachusetts License Registration
1976	American Board of Internal Medicine Certificate
1979	American Board of Internal Medicine/Medical Oncology Certificate

Academic Appointments

1978-1979	Instructor in Medicine, Harvard Medical School Boston, Massachusetts
1979-1982	Assistant Professor of Medicine, Sidney Farber Cancer Institute Harvard Medical School
1982-1984	Assistant Professor of Medicine, Harvard Medical School
1984-1987	Associate Professor of Medicine, Harvard Medical School
1987-1998	Associate Clinical Professor of Medicine, Harvard Medical School
1998-	Clinical Professor of Medicine, Harvard Medical School

Hospital Appointments

1976-1978	Assistant in Medicine, Peter Bent Brigham Hospital
1978-1979	Clinical Associate, Dana-Farber Cancer Institute
1978-1984	Assistant Physician, Dana-Farber Cancer Institute
1978-1982	Junior Associate in Medicine, Brigham and Women's Hospital
1981-1989	Consulting Physician, Nantucket Cottage Hospital, Nantucket, Massachusetts

Other Professional and Major Visiting Appointments

1987-1994	Vice President, Clinical Development, Genetics Institute
1994-	Executive Vice President, Praecis Pharmaceuticals, Inc., Cambridge, Massachusetts
1994-	Chief Medical Officer and Chief Regulatory Officer Praecis Pharmaceuticals, Inc.

Awards and Honors

1968	Magna Cum Laude, Bowdoin College
1968	Phi Beta Kappa, Bowdoin College
1972	Alpha Omega Alpha, University of Pennsylvania School of Medicine
1992, 1994, 1996,	Listed in Best Doctors in America, Published by Woodward/White, Aiken, South Carolina
1996	Board of Trustees, Bowdoin College, Brunswick, Maine
1996	Executive Committee, Head of the Charles Regatta, Cambridge, Massachusetts
2002	Chairperson, Admissions and Financial Aid Committee of the Board of Trustees, Bowdoin College, Brunswick, Maine
1998	Listed Best Doctors in America
2000 2004	Listed Best Doctors in America
2002 2004	Listed America's Top Doctors
2004	Director and Manager, Maria Mitchell Association, Nantucket MA
2005	Recipient Distinguished Medical Alumni Service Award, University of Pennsylvania School of Medicine

Major Committee Assignments

National/Regional	
1979	Consultant, National Academy of Sciences Task Force on Saccharin Labeling Act

1986-	Member, Progression/Response Subcommittee on Prostate Cancer, through the Organ Systems Coordinating Center, Roswell Park Memorial Institute, Buffalo, New York
1987	Panel Member, NIH Consensus Localized Prostate Cancer, Bethesda, Maryland
1987-	Consultant, National Kidney and Urologic Diseases Advisory Board
1992-	Reviewer, SPORE Grant for Prostate Cancer, National Institutes of Health
1995	Reviewer, SPORE Grant for Prostate Cancer, National Institutes of Health
1995	Reviewer for WW Smith and Mary L Smith Charitable Trust Foundations, Bryn Mawr, Pennsylvania
1996	Member, National Cancer Institute Working Group for Cancer Prevention

Medical

1980-1987	Admissions Committee (Subcommittee III), Harvard Medical School
-----------	---

Hospital

1978-1979	Chairman, Cardiopulmonary Resuscitation Review Committee, Dana-Farber Cancer Institute
1980-1983	Member, Biomedical Research Grant Review Committee, Dana-Farber Cancer Institute
1982-1987	Member, Scientific Protocol Review Committee, Dana-Farber Cancer Institute
1985-1987	Member, Free Care Committee, Dana-Farber Cancer Institute
1985-1987	Member, Internship Selection Committee, Dana-Farber Cancer Institute
1985-1987	Member, Clinical Planning Committee, Dana-Farber Cancer Institute
1997-	Co-Chair, Hershey Gift for Basic and Clinical Prostate Cancer Research Beth Israel Deaconess Medical Center

Memberships, Offices and Committee Assignments in Professional Societies

1979	American Association for Cancer Research
1979	American Society of Clinical Oncology
1979-1982	Member, American College of Physician
1980-	American Federation for Clinical Research
1980-	Guest Member, American Urological Association, New England Section
1982-	Fellow, American College of Physicians
1983-	Affiliate Member, American Urological Association
1985-1993	Member, New England Cancer Society
1988-	Corresponding Member, Argentinian Urological Association
1988	Chairman, Nominating Committee, American Society of Clinical Oncology
1988-1994	Member, American Society of Hematology
1990-1994	Corporate member, Society for Biological Therapy
1992-1995	Member, Medical Relations Committee, Pharmaceutical Manufacturer's Association
1992-1994	Chairperson, Medical Physicians Educational Program Pharmaceutical Manufacturer's Association
1994-1996	Board of Trustees, American Academy of Pharmaceutical Physicians
1998-	Corresponding Member, European Association of Urology

Editorial Board	1999	BOARD OF DIRECTORS, GENOME THERAPEUTICS CORP.
	1983-1985	Editorial Board, Journal of Nutrition, Growth and Cancer
	1985-1988	Editorial Board, Journal of Clinical Oncology
	1989-1992	Board of Consultants, Journal of Urology
	1996-	Reviewer, New England Journal of Medicine
	1996-	Reviewer, Annals of Internal Medicine
	1996-	Reviewer, Urology
	1997-	Editorial Board, Molecular Urology
	1997-	Editorial Board, Urologic Oncology Case Management
	1997-	Editorial Board, Harvard Men's Health Watch

Research Funding Information

Past:	1979-1986	NIH/NCI/Contract Investigator contract to study new Phase I anti-cancer agents
	1982-1984	Abbott Laboratories PI Principal Investigator on Phase I-III Evaluations of Leuprolide Acetate for Prostate Cancer
	1985	NIH/CRC/BWH Investigator Collaborator to study effects of radiation on thyroid function of long term cancer survivors
	1987	Biogen Corporation PI Principal Investigator on Phase I-III Evaluations of Interferon Gamma for Advanced Renal Cancer
Current:	1997-	Hershey Gift for Prostate Cancer Research (BIDMC) Co-PI Benefaction for study of basic and clinical aspects of prostate cancer

Principal Clinical and Hospital Service Responsibilities

1978-1987	Medical Oncology, Attending Physician, Dana-Farber Cancer Institute (2 months per year)
1978-1987	Attending for Medical Oncology Consult Service, Brigham and Women's Hospital (1 month per year)
1981-1987	Medical Attending Physician, Ward Service, Brigham and Women's Hospital (1 month per year)
1985-1987	Attending for Medical Consult Service, Beth Israel Hospital (1 month per year)
1987-1996	Outpatient Attending Responsibilities, Dana-Farber Cancer Institute
1996-	Outpatient Attending Responsibilities, Beth Israel Deaconess Medical Center

Self Report of Teaching

1978-1987	Medical Oncology, Attending Physician, Dana-Farber Cancer Institute (2 months per year): 2-3 medical students; 2-3 interns; 2 residents; 4-5 fellows; 2 lectures per week; rounds 6 times per week; outpatient attending for medical oncology fellow
-----------	---

1978-1988 **Attending for Medical Oncology Consult Service, Brigham and Women's Hospital** (1 month per year); 1 fellow, 1 resident

1979-1981 **Preceptor, Introduction to Clinical Medicine (ICM), Harvard Medical School:** Preceptor for history and physical examination of general internal medicine patient; 2 students/year; 1 lecture per week

1980-1988 **Cancer Medicine, Lecturer on Urologic Cancer, course under direction of DCE, Harvard Medical School**

1980-1988 **Primary Care Medicine Course, Lecturer on Prostate Cancer, course under direction of DCE, Harvard Medical School (Dr. Branch)**

1981-1987 **Medical Attending Physician, Ward and HCHP Services, Brigham and Women's Hospital** (1 month per year): 2-3 medical students; 2-3 interns; 1 resident; 2-4 lectures per week; rounds 6 times per week

1984-1990 **Intensive Review of Internal Medicine, Lecturer on Urologic Cancer, course under direction of DCE, Harvard Medical School**

1985-1987 **Attending for Medical Oncology Consult Service, Beth Israel Hospital** (1 month per year); 1 resident; 1 medical student; 2-3 fellows; 2 lectures/week; rounds 4 times per week

1990-1992 **Genitourinary Oncology Course, Lecturer, Massachusetts General Hospital, DCE, HMS**

1995- **Lecturer, Second Year Pathophysiology Course, Harvard Medical School (Endocrinology related to the management of cancer)**

Advising Responsibilities

1979-1982 **Advisor for Health Science and Technology-Harvard Medical School (HMS-HST), student thesis (anthracycline research)**

1983-1985 **Internship Advisor (for fourth year Harvard Medical Students (1 student/year))**

1983-1985 **Tutor in Medical Sciences, Harvard Medical School**

1986-1987 **Advisor for Health Science and Technology-Harvard Medical School (HMS-HST), student thesis (testis cancer); Presented at Soma Weiss Assembly**

Leadership Roles

1982-1996 **Course Founder, Co-Director and Organizer, Urologic Cancer Course, a biannual course under the auspices of the Department of Continuing Education (DCE), Harvard Medical School**

- 1996 **Course Co-Director, First International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer** (International CME granting conference, with associated publication)
- 1997 **Course Co-Director, Second International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer** (International CME granting conference, with associated publication)
- 1998 **Course Co-Director, Third International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer** (International CME granting conference, with associated publication)
- 1999 **Course Co-Director, Fourth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer** (International CME granting conference, with associated publication)
- 1996-present **Hershey Family Foundation for Basic and Clinical Prostate Cancer Research, Beth Israel Deaconess Medical Center** (Founder and Originator)

Regional, National and International Contributions

Invited Presentations

- 1980-present Medical Grand Rounds; on topics of Urologic Oncology, Prostate Cancer and Hematopoietic Growth Factors, at hospitals throughout the United States, Mexico, Canada, and Europe, at 4-8 hospitals per year
- 1980-present Oncology Rounds, Tumor Conferences, Regional Symposia, National Symposia, International Congresses, on Urologic oncology, especially prostate cancer, 8-10 presentations per year
- 1990-1994 Scientific Symposia and Meet the Professor Sessions of both Regional and National American Society of Clinical Oncology (ASCO) Meetings
- 1995 Testicular Cancer Update, American Urological Association CME course National Meeting, Course Faculty
- 1996 Update in Prostate Cancer Treatments, a series of 10 regional meetings sponsored by the University of Kentucky CME department, throughout academic centers nationwide
- 1997-present Update in Internal Medicine, Harvard Medical School Department of Continuing Education, Beth Israel Deaconess Medical Center Course Faculty
- 1998-present International Prostate Cancer Update, Sponsored by Medical Education Collaborative, Course Faculty
- 1998-present Lecturer, Testicular Cancer, Beth Israel Deaconess Medical Center
- 1999 Ninth International Congress on Anti-Cancer Treatment, Chaired Symposium on Prostate Cancer

2003- International Faculty, European Association of Urology, Annual Meeting,
Madrid Spain March 2003, on Prostate Cancer

2003 DIRECTOR, HARVARD MEDICAL SCHOOL SPONSORED COURSE. "PROSTATE
CANCER FOR INTERNISTS, DEPARTMENT OF CONTINUING OF MEDICAL EDUCATION

Bibliography

Original Reports

1. Bennion LJ, Ginsberg RL, Garnick MB, Bennett PH. Effect of oral contraceptives on the gallbladder bile of normal women. *N Engl J Med* 1976;294:189-194.
1. Bennion LJ, Ginsberg RL, Garnick MB, Bennett PH. Effects of the normal menstrual cycle on human gallbladder bile. *N Engl J Med* 1976;294:1187.
3. Ginsberg RL, Garnick MB. Effect of phenobarbital on biliary lipid metabolism in normal man. *Gastroenterology* 1977;72:1221-1227.
4. Mayer RJ, Garnick MB, Steele GD Jr., Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. *Cancer* 1978;42:1428-1433.
5. Mirel R, Garnick MB. Skin tests, procaine penicillin G and pseudoanaphylaxis. *JAMA* 1978;240:1751-1752.
6. Bennion LJ, Drobny E, Knowler WC, Ginsberg RL, Garnick MB, Adler RD, Duane WC. Sex differences in the size of bile acid pools. *Metabolism* 1978;27:961-969.
7. Garnick MB, Lokich JJ. Primary malignant melanoma of the rectum: rationale for conservative surgical management. *J Surg Oncology* 1978;10:529-531.
8. Israel M, Pegg WJ, Wilkinson PM, Garnick MB. Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. *J Liquid Chromatography* 1978;1:795-809.
9. Israel M, Pegg WJ, Wilkinson PM, Garnick MB. High performance liquid chromatography in the analysis of adriamycin and analogs in biological fluids. In: Hawk GL, ed. *Biological-biomedical applications of liquid chromatography*. New York: Marcel Dekker, Inc., 1979:413-428.
10. Garnick MB, Bennett PH, Langer T. Low density lipoprotein metabolism and lipoprotein cholesterol content in Southwestern American Indians. *J Lipid Res* 1979;20:31-39.
11. Garnick MB, Canellos GP, Richie JP, Stark JJ. Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-diamminedichloroplatinum, vinblastine, and bleomycin remission induction followed by cyclophosphamide and adriamycin. *Cancer Treat Rep* 1979;63:1681-1686.
12. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III. The initial clinical evaluation of N-trifluoroacetyl-adriamycin-14-valerate (AD 32), an adriamycin analog. *Cancer Treat Rep* 1979;63:919-923.
13. Garnick MB, Skarin AT, Steele GD Jr. Metastatic carcinoma of the penis: Complete remission following high dose methotrexate chemotherapy. *J Urol* 1979;122:265-266.

14. Lokich JJ, Garnick MB, Legg M. Intralesional immune therapy: methanol extraction residue of BCG (MER-BCG) or purified protein derivative (PPD). *Oncology* 1979;36:236-241.
15. Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin during L-asparaginase therapy. *N Engl J Med* 1979;301:252-253.
16. Garnick MB, Ensminger WD, Israel M. A clinical pharmacological evaluation of hepatic arterial infusion of adriamycin. *Cancer Research* 1979;39:4105-4110.
17. Todd RF III, Garnick MB. Prostatic adenocarcinoma, sarcoidosis, and hypercalcemia: an unusual association. *J Urol* 1980;123:133-134.
18. Garnick MB, Blum RH, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LH, Frei E III. Phase I trial of bruceantin. *Cancer Treat Rep* 1980;63:1929-1932.
19. Frei E III, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with citrovorum factor rescue: rationale and spectrum of antitumor activity. *Am J Med* 1980;68:370-376.
20. Garnick MB. Spurious rise in human chorionic gonadotropin induced by marihuana in testis cancer patients. *N Engl J Med* 1980;303:1177.
21. Todd RF III, Garnick MB, Canellos GP, Richie JP, Gittes RF, Mayer RJ, Skarin AT. Phase I-II trial of methylglyoxal-bis-guanyldrazone (Methyl-G) in the treatment of patients with metastatic renal adenocarcinoma. *Cancer Treat Rep* 1981;65:17-20.
22. Hermann VM, Garnick MB, Moore FD, Wilmore DW. Effect of combination chemotherapy on protein kinetics in patients with metastatic cancer. *Surgery* 1981;90:381-387.
23. Garnick MB. Advanced renal cell cancer. *Kidney International* 1981;20:127-136.
24. Weiss GR, Garnick MB. Testicular cancer in a Russell-Silver dwarf. *J Urol* 1981;126:836-837.
25. Frei E III, Garnick MB, Ensminger WD, Israel M, Kaplan WD, Come SE. Biochemical pharmacology in medical oncology. *Cancer Treat Rep* 1981;65 (Supplement 3):21-26.
26. Richie JP, Garnick MB, Finberg H. Computed tomography: How accurate for abdominal staging of testis tumors? *J Urol* 1982;127:715-717.
27. Fram RJ, Garnick MB, Retik A. The spectrum of genitourinary abnormalities in patients with cryptorchidism, with emphasis on testicular carcinoma. *Cancer* 1982;50:2243-2245.
28. Waters WB, Garnick MB, Richie JP. Complications of retroperitoneal lymphadenectomy in the management of nonseminomatous testis tumors. *Surg Gynecol Obstet* 1982;154:501-504.
29. Richie JP, Birnholz J, Garnick MB. Ultrasonography as a diagnostic adjunct for the evaluation of scrotal masses. *Surg Gynecol Obstet* 1982;154:695-698.

30. Hickey WF, Garnick MB, Henderson IC, Dawson DM. Primary cerebral venous thrombosis in patients with cancer - a rarely diagnosed paraneoplastic syndrome. *Am J Med* 1982;73:740-750.
31. Todd RF III, Garnick MB, Canellos GP. Phase II trial of combination Methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma. *Cancer Treat Rep* 1982;66:1585-1586.
32. Balikian JP, Jochelson MS, Bauer KA, Skarin AT, Garnick MB, Canellos GP, Smith EH. Pulmonary complications of chemotherapy regimens containing bleomycin. *AmJRoentg* 1982;139:455-461.
33. Anderson KC, Cohen GI, Garnick MB. Phase II trial of mitoxantrone. *Cancer Treat Rep* 1982;66:1929-1931.
34. Li FP, Little JB, Bech-Hansen NT, Paterson MC, Arlett C, Garnick MB, Mayer RJ. Acute leukemia after radiotherapy in a Turcot's Syndrome patient: impaired cultured skin fibroblast colony formation after X-irradiation. *Am J Med* 1983;74:343-348.
35. Kaplan MM, Garnick MB, Gelber R, Li FP, Larsen PR, Cassady JR, Sallan SE, Fine WE, Sack MJ. Risk factors for thyroid abnormalities after neck irradiation for childhood cancer. *Am J Med* 1983;74:272-280.
36. Garnick MB, Weiss GR, Steele GD Jr., Israel M, Schade D, Sack MJ, Frei E III. Clinical evaluation of long-term, continuous-infusion doxorubicin. *Cancer Treat Rep* 1983;67:133-142.
37. Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. *Am J Med* 1983;74:557-563.
38. Kaplan WD, Garnick MB, Richie JP. Iliopelvic radionuclide lymphoscintigraphy in patients with testicular cancer. *Radiology* 1983;147:231-235.
39. Weiss GR, Garnick MB, Osteen RT, Steele GD Jr, Wilson RE, Schade D, Kaplan WD, Boxt LM, Kandarpa K, Mayer RJ, Frei E III. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable pump. *J Clin Oncol* 1983;1:337-344.
40. Garnick MB, Griffin JD. Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. *Ann Intern Med* 1983;98:926-27.
41. Anderson KC, Garnick MB, Meshad MW, Cohen GI, Pegg WJ, Frei E III, Isreal M, Modest E, Canellos GP. Phase I trial of Mitoxantrone By 24 Hour continuous infusion. *Cancer Treat Rep* 1983;67:435-438.
42. Richie JP, Garnick MB, Seltzer S, Bettmann MA. Computed tomography scan for diagnosis and staging of renal cell carcinoma. *J Urol* 1983;129:1114-1116.

43. Garnick MB, Koerner FC. Case records of the Massachusetts General Hospital. A 32-year old man with testicular enlargement and pulmonary intravascular carcinoma. *N Engl J Med* 1983;309:477-487.
44. Garnick MB, Canellos GP, Richie JP. Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. *JAMA* 1983;250:1733-1741.
45. Karp GI, von Oeyen P, Valone F, Khetarpal VK, Israel M, Mayer RJ, Frigoletto FD, Garnick MB. Doxorubicin in pregnancy: possible transplacental passage. *Cancer Treat Rep* 1983;67:773-777.
46. Lederman GS, Garnick MB, Canellos GP, Richie JP. Chemotherapy of refractory germ cell cancer with Etoposide. *J Clin Oncol* 1983;1:706-709.
47. Garnick MB, Schade D, Israel M, Maxwell B, Richie JP. Intravesical Doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. *J Urol* 1984;131:43-46.
48. Andriole GL, Bettmann MA, Garnick MB, Richie JP. Indwelling double-J ureteral stents for temporary and permanent urinary drainage: experience with 87 patients. *J Urol* 1984;131:239-241.
49. Garnick MB, Young RH. Case Records of the Massachusetts General Hospital. Right orbital mass after treatment for a seminoma. *N Engl J Med* 1984;310:1446-1455.
50. Richie JP, Garnick MB. Changing concepts in the treatment of nonseminomatous germ cell tumors of the testis. *J Urol* 1984;131:1089-1092.
51. Jochelson MS, Garnick MB, Balkian JP, Richie JP. The efficacy of routine whole lung tomography in germ cell tumors. *Cancer* 1984;54:1007-1009.
52. Kaplan WD, Come SE, Takvorian RW, Laffin SM, Gelman RS, Weiss GR, Garnick MB. The clinical significance of pulmonary Tc-99m macroaggregated albumin following radionuclide hepatic artery perfusion. *J Clin Oncol* 1984;2:1266-1269.
53. The Leuprolide Study Group (Garnick MB, Glode LM, Writing Committee). Leuprolide versus Diethylstilbestrol for metastatic prostate cancer. *N Engl J Med* 1984;311:1281-1286.
54. Garnick MB, Glode LM, Smith JA Jr, Max DT. Leuprolide: its effects in comparison with diethylstilbestrol in the treatment of advanced cancer of the prostate. *British Journal of Clinical Practice* 1985;39:20-23.
55. Nichols CR, Hoffman, Einhorn LH, Williams SD, Wheeler LA, Garnick MB. Hematologic malignancies associated with primary mediastinal germ cell tumors. *Ann Intern Med* 1985;102:603-609.
56. Rieker PR, Edbril SD, Garnick MB. Curative testis cancer therapy: social and emotional consequences. *J Clin Oncol* 1985;3:1117-1126.

57. Friedman EL, Garnick MB, Stomper PC, Mauch PM, Harrington DP, Richie JP. Therapeutic guidelines and results in advanced seminoma. *J Clin Oncol* 1985;3:1325-1332.
58. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses following chemotherapy for nonseminomatous testicular cancer: CT-histologic correlation. *AJR* 1985;145:743-746.
59. Andriole GL, Garnick MB, Richie JP. Unusual behavior of low-grade, low-stage transitional cell carcinoma of the bladder. *Urology* 1985;25:524-526.
60. Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. *Urology* 1986;27:21-26.
61. Stomper PC, Jochelson MS, Friedman EL, Garnick MB, Richie JP. CT evaluation of advanced seminoma treated with chemotherapy. *AJR* 1986;146:745-748.
62. Lederman GS, Garnick MB. Possible benefit of doxorubicin treatment in refractory germ cell cancer. *Cancer* 1986;58:2393-2398.
63. Glode LM, Smith JA Jr, Leuprolide Study Group. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide. *J Urol* 1987;137:57-60.
64. Licht JD, Garnick MB. A Phase II trial of streptozotocin in the treatment of advanced renal cell carcinoma. *Cancer Treat Rep* 1987;1:97-98.
65. Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. *J Urol* 1987;137:1236-1237.
66. Kalish LA, Garnick MB, Richie JP. A determination of appropriate endpoints in assessing efficacy of intravesical therapies in superficial bladder cancer. *J Clin Oncol* 1987;5:2004-2008.
67. Richie JP, Socinski MA, Fung CY, Brodsky GL, Kalish LA, Garnick MB. Management of patients with clinical stage I or stage II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options. *Arch Surg* 1987;122:1443-1445.
68. Stomper PC, Fung CY, Socinski MA, Jochelson MS, Garnick MB, Richie JP. Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. *AJR* 1987;149:1187-1190.
69. Talcott JA, Garnick MB, Stomper PC, Godleski JJ, Richie JP. Cavitary lung nodules associated with combination chemotherapy containing bleomycin. *J Urol* 1987;138:619-620.
70. Garnick MB. New advances and directions in testicular cancer. *Rev Bras Cancerol* 1987;323-329

71. Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. *J Urol* 1988;139:251-255.
Reply to correspondence. *J Urol* 1989;141:140.
72. Socinski MA, Garnick MB. Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients. *Ann Intern Med* 1988;108:567-568.
73. Stomper PC, Socinski MA, Kaplan WD, Garnick MB. Failure patterns of nonseminomatous testicular germ cell tumors: radiographic analysis of 51 cases. *Radiology* 1988;167:641-646.
74. Fung CY, Kalish LA, Brodsky GL, Richie JP, Garnick MB. Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology. *J Clin Oncol* 1988;6:1467-1473.
75. Donahue RE, Seehra J, Metzger M, Lefebvre D, Rock B, Carbone S, Nathan DG, Garnick M, Sehgal PK, Laston D, LaVallie E, McCoy J, Schendel P, Norton C, Turner K, Yang YC, Clark SC. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. *Science* 1988;241:1820-1823.
76. Rogers LA, Longtine JA, Garnick MB, Pinkus GS. Silicone lymphadenopathy in a long distance runner: complication of a silastic prosthesis. *Human Pathology*. 1988;19:1237-1239.
77. Socinski MA, Garnick MB, Stomper PA, Fung CA, Richie JP. Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low-volume retroperitoneal disease. *J Urol* 1988;140:1437-1441.
78. Garnick MB. The comparative role of prostate-specific antigen and acid phosphatase in metastatic prostate cancer. In: Coffey D, Karr JP, Catalona W, eds. *Clinical aspects of prostate cancer: assessment of new diagnostic and management procedures*. New York: Elsevier. 1989:220-232.
79. Ulich TR, del Castillo J, Watson LR, Yin S, Garnick MB. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. *Blood* 1990;75:846-850.
80. Sharifi R, Soloway M, Correa RJ, Glass AG, Guinan PD, Garnick MB, Glode LM, Smith JA, Stein BS. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. *J Urol* 1990;143:68-71.
81. Rieker PP, Fitzgerald EM, Kalish LA, Richie JP, Lederman GS, Edbril SD, Garnick MB. Psychosocial factors, curative therapies and behavioral outcomes. A comparison of testis cancer survivors and a control group of healthy men. *Cancer* 1989;64:2399-2407.
82. Lederman GS, Herman TS, Jochelson M, Silver BJ, Chaffey JT, Garnick MB, Richie J, Sheldon TA, Coleman CN. Radiation therapy of seminoma: 17-year experience at the Joint Center for Radiation Therapy. *Radiother Oncol* 1989;14:203-208.

83. Gillio AP, Gasparetto C, Laver J, Abboud M, Bonilla MA, Garnick MB, O'Reilly RJ. Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. *J Clin Invest* 1990;85:1560-1565.
84. Garnick MB, Stoudemire JB. Preclinical and clinical evaluation of recombinant human macrophage colony stimulating factor (rhM-CSF). *International Journal of Cell Cloning* 1990;8:356-373.
85. Munn DH, Garnick MB, Cheung NKV. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype and antitumor cytotoxicity in non-human primates. *Blood* 1990;75:2042-2048.
86. Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan. *Clinical Nuclear Medicine* 1990;15:485-487.
87. Stoudemire JB, Garnick MB. Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. *Blood* 1991;77:750-755.
88. Kantoff PW, Kalish LA, McDowell-Bryant P, Canellos GP, Gibbs R, Richie JP, Garnick MB. Long-term followup of 150 patients with testicular cancer treated at a single institution. *J Urology* 1992;147:82-88.
89. Garnick MB, Abels R, Rudnick SA. The role of recombinant human erythropoietin in the management of anemia associated with acquired immunodeficiency syndrome. *Contrib Nephrol* 1991;88:282-294.
90. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? *Radiology* 1991;180:711-714.
91. Rose RM, Kobzik L, Dushay K, Wolfthal S, Hondalus M, Metzger M, Stoudemire J, Brain JD, Garnick M, O'Donnell C, Donahue RE. The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates. *Am Rev Respir Dis* 1992;146:1279-1286.
92. Jakubowski A, Bajorin D, Templeton MA, Chapman P, Cody B, Sherman ML, Garnick MB, Houghton A. Phase I study of continuous infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. *Clin Cancer Res* 1996;2:295-302.
93. Tepler I, Elias L, Smith II JW, Hussein M, Rosen G, Chang A Y-C, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA. A randomized trial of recombinant human interleukin eleven in cancer patients with a history of severe thrombocytopenia due to chemotherapy. *Blood* 1996;87:3607-3614.
94. Olumi A, Garnick MB, Benson, C, Renshaw, A, Richie, JP. Leydig cell hyperplasia mimicking testicular neoplasm. *Urology* 1996;48:647-649.

95. Crawford, ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, Garnick MB, Porterfield HA. Comparison of Perspectives on Prostate Cancer: Analyses of Survey Data. *Urology* 1997, 50:366-372.
96. Garnick MB, Ferry J. Case Records of the Massachusetts General Hospital. Hematologic abnormalities in a 23 year old man with extragonadal germ cell cancer. *N Engl J Med* (1997, December 25)
97. Molineaux, CJ., Sluss, PM., Bree, MP., Geftter, ML., Sullivan, LM., Garnick, MB. Suppression of Plasma Gonadotropins by Abarelix, A Potent New LHRH Antagonist. *Molecular Urology* 1998, 2;3, 265-268.
98. Garnick, MB., and Fair., WR. Combating Prostate Cancer. *Scientific American* December 1998, 75-83.
99. Garnick, MB, and Campion, M. Abarelix Depot, a GnRH Antagonist, v. LHRH Superagonists in Prostate Cancer: Differential Effects on Follicle-Stimulating Hormone. *Molecular Urology* 2000, Vol. 4, Number 3; 275:277.
100. Tomera, K; Gleason, D; Gittelman, M; Moseley, W; Zinner, N; Murdoch, M; Menon, M; Campion, M; and Garnick, MB. The gonadotropin-releasing hormone antagonist Abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. *J Urol* 2001;165:1585-1589.
101. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, and Garnick, MB. A phase 3, multicenter, open-label, randomized study of Abarelix versus leuprolide acetate in men with prostate cancer. *Urology* 2001;58:756-761.
102. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, and Garnick MB. A phase 3, multicenter, open-label, randomized study of Abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. *J Urol* 2002;167:1670-1674.
103. Garnick MB. Cancer. *World Book Encyclopedia*, World Book Publications. 2003
104. Garnick MB. Screening for prostate cancer. PIER module for the American College of Physicians accessed through www.acponline.org. 2004
105. Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, CampionM, Garnick MB. An open label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. *Urology* 2003; 62:877-882
106. Wong SL, Lau DTW, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. *Clin Pharmacol Ther* 2003;73:304-11.
107. Wong SL, Lau DTW, Baughman SA, Fotheringham N, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a

gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50-75. *J Clin Pharmacol* 2004;44:495-502.

Proceedings of Meetings

1. Garnick MB, Rieselbach RE. Renal complications of cancer therapy. In: *Proceedings, 8th International Congress of Nephrology: advances in basic and clinical nephrology*. Thessaloniki, Greece: University Studio, 1981:1192-1198.
2. Frei E III, Friedell G, Garnick MB, Howe AE, Ingelfinger J, Moskowitz PS, Rieselbach RE, Soloway M, Woolley P. (Genitourinary Workshop). Summary and prospective statement concerning the genitourinary workshop. *Cancer Clin Trials Supplement* 1981;4:24-29.
3. Garnick MB, Griffin JD, Sack MJ, Blum RH, Israel M, Frei E III. Phase II evaluation of N-trifluoroacetyl Adriamycin-14-valerate (AD 32). In: Muggia FM, Young CW, Carter SK, eds. *Anthracycline antibiotics in cancer therapy. Proceedings of the International Symposium on anthracycline antibiotics in cancer therapy*, New York, New York, 16-18 September 1981. The Hague: Martinus Nijhoff, 1982:541-548.
4. Garnick MB, Maxwell B, Gibbs RS, Richie JP. Intravesical doxorubicin for prophylaxis in the management of superficial bladder carcinoma - an update. In: Howell SB, ed. *Intra-arterial and intracavitary chemotherapy 1984. Proceedings of the University of California, San Diego Cancer Center conference on intra-arterial and intracavitary chemotherapy*, February 24-25, 1984. Boston: Martinus Nijhoff, 1984:211-217.
5. Garnick MB for the Leuprolide Study Group. Long-term efficacy of the GnRH analogue, Leuprolide (Lupron) in metastatic prostate cancer. In: Ishigami J, ed. *Recent advances in chemotherapy. Anticancer Section 2. Proceedings of the 14th International Congress of Chemotherapy*, Kyoto, Japan, 1985. Tokyo: University of Tokyo Press, 1985.
6. Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer - results of a prospectively randomized trial: an update. In: Garnick MB, ed. *New hormonal treatments for prostate cancer: current status and new developments with emphasis on the LHRH analogues. Proceedings of a workshop held at the 14th International Congress of Chemotherapy*, Kyoto, 1985. Tokyo: University of Tokyo Press, 1986.
7. Garnick MB, ed. *New hormonal treatments for prostate cancer: current status and new developments with emphasis on the LHRH analogues. Proceedings of a workshop held at the 14th International Congress of Chemotherapy*, Kyoto, Japan, 1985. Tokyo: University of Tokyo Press, 1986.
8. Swanson LJ, Garnick MB. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. In: Klijn JGM, Paridaens R, Foekens JA, eds. *hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer. Volume 18*. New York: Raven Press, 1987:301-308.
9. Tondini C, Garnick MB. Chemotherapy for extragonadal and poor-prognosis germ cell cancers: the Dana-Farber Cancer Institute approach. In: Johnson DA, Logothetis C, von

Eschenbach AC, ed. Systemic therapy for genitourinary cancers. Chicago: Yearbook Medical Publishers, 1989:370-379.

10. Garnick MB, Swanson LJ, Max DT for the Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer: a multicenter study. In: Johnson DA, Logothetis C, von Eschenbach AC, eds. Systemic therapy for genitourinary cancers. Chicago: Yearbook Medical Publishers, 1989:179-188.
11. Soloway MS, Murphy WM, Johnson DE, Farrow GM, Paulson DF, Garnick MB. Summary of a workshop on initial evaluation and response criteria for patients with superficial bladder cancer. *Br J Urol* 1990;66:380-385.
12. Stoudemire JB, Garnick MB. In Vivo Evaluations of Recombinant Human Macrophage Colony Stimulating Factor (rhM-CSF). In: Freund, Link, Welte, eds. Proceedings of the First International Symposium on Cytokines in Hematopoiesis, Oncology, and AIDS, June 14-17, 1989, Hannover, Federal Republic of Germany. Berlin: Springer-Verlag, 1990:459-468.
13. Soloway MS, Murphy WM, Johnson DE, Farrow GM, Paulson DF, Garnick MB. Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop. *Br J Urol* 1990;66:380-385.
14. Garnick MB, Fair WR. First international conference on neoadjuvant hormonal therapy of prostate cancer: overview consensus statement. *Urology* 1997;49(suppl3A):1-4.
15. Garnick MB. Hormonal therapy in the management of prostate cancer: From Huggins to the present. *Urology* 1997;49(Suppl 3A):5-15.
16. Garnick MB, Fair WR. Third International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer March 13-14, 1998. *Molecular Urology* 1998; 2; 3.
17. Garnick MB, Fair WR. Fourth International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: Overview of Consensus Statement. *Molecular Urology* 1999; 3; 3:171-174.

Reviews and Educationally Relevant Publications

Reviews

1. Garnick MB, Mayer RJ. Acute renal failure associated with neoplastic disease and its treatment. *Seminars in Oncology* 1978;5:155-165.
2. Garnick MB, Garnick BK. Policy statement on the Saccharin Study and Labeling Act. *Boston Herald American* July 9, 1980;A9.
3. Garnick MB, Mayer RJ. Management of acute renal failure associated with neoplastic disease. *Oncologic Emergencies* 1981;247-271.
4. Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. *Cancer* 1981;48:1539-1549.
5. Robert N, Garnick MB, Frei E III. Cancers of unknown origin: current approaches and future perspectives. *Seminars in Oncology* 1982;9:526-531.
6. Anonymous. Estramustine for prostate cancer. *Med Lett Drugs Ther* 1982;24:74.
7. Anonymous. Etoposide (VP-16-213 VePesid-Bristol) *Med Lett Drugs Ther* 1984;26:48-49.
8. Goldberg I, Garnick MB, Bloomer WB. Urinary tract toxic effects of cancer therapy. *J Urol* 1984;132:1-6.
9. Garnick MB. An implanted infusion pump for chemotherapy of liver metastases. *Med Lett Drug Ther* 1984;26:89-90.
10. Garnick MB. Novel endocrine approaches in the management of prostate cancer and Intravesical therapies in the management of superficial bladder cancer. *Mediguide to Oncology* 1985;5:1-9.
11. Garnick MB, Glode LM, Smith JA Jr, Max DT. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate. *Br J Clin Pract Symp Suppl* 1985;37:8-12.
12. Anonymous. Leuprolide for prostate cancer. *Med Lett Drug Ther* 1985;27:71-72.
13. Garnick MB. Prostate carcinoma: an Internist's view. *Medical Times* 1985;113:40-46.
14. Garnick MB. Prostate carcinoma: an Internist's view. *Resident and Staff Physician* 1985;3PC-7PC.
15. Anonymous. Interferon for treatment of cancer. *Med Let Drug Ther* 1986.
16. Garnick MB. The current status of endocrine therapy for prostate cancer. *Oncology* 1987;1:19-25.
17. Anonymous. Interleukin-2. *Med Let Drug Ther* 1987;29:88-89.

18. Anonymous. Mitoxantrone. Med Let Drug Ther 1988.
19. Swanson LJ, Seely JH, Garnick MB. Gonadotropin releasing hormone analogs and prostatic cancer. CRC Critical Reviews in Oncology/Hematology 1988;8:1-26.
20. Fung CY, Garnick MB. Clinical stage I carcinoma of the testis. J Clin Oncol 1988;6:734-750.
21. Anonymous. Flutamide. Med Let Drug Ther 1989;31:72.
22. Garnick MB. Testicular Cancer. Seminars in Surgical Oncology 1989;5:221-226.
23. Anonymous. Carboplatin. Med Let Drug Ther 1989;31:83-84.
24. Anonymous. Ifosfamide and mesna. Med Let Drug Ther 1989;31:98-99.
25. Anonymous. Levamisol with Fluorouracil for Colon Cancer. Med Let Drug Ther 1989; 31:89-90.
26. Anonymous. Goserelin. Med Let Drug Ther 1990;32:102.
27. Anonymous. Interleukin-2. Med Let Drug Ther 1990; 32:85-86.
28. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Medical progress: biology and management of bladder cancer. N Engl J Med 1990;322:1129-1138.
Reply to correspondence. N Engl J Med 1991;324:126.
29. Anonymous. Idarubicin HCL (Idamycin). Med Let Drug Ther 1991; 33: 83-85.
30. Anonymous. Granulocyte stimulating factors. Med Let Drug Ther 1991; 33:61-63.
31. Garnick MB. Prostate cancer: screening, diagnosis and management. Ann Intern Med. 1993;118:804-818.
Reply to correspondence. Ann Int Med 1993;119:1054-1055.
32. Garnick MB. The dilemmas of prostate cancer. Scientific American 1994;270:52-59.
Reply to correspondence. Scientific American 1994; Aug. p 9.
33. Calcianno R, Chodak GW, Garnick MB, Kuban DA, Resnick, MI. The prostate cancer conundrum. Patient Care 1995; 29: 84-104.
34. Calcianno R, Chodak GW, Garnick MB, Kuban DA, Resnick, MI. Getting the most out of PSA testing. Patient Care 1995; 29: 104-109.
35. Garnick MB, Fair, WR. Prostate Cancer - Emerging Concepts. Part I. Ann Intern Med 1996;125:118-125.
**
36. Garnick MB, Fair, WR. Prostate Cancer - Emerging Concepts. Part II. Ann Intern Med 1996;125:205-212.
Reply to correspondence: Ann Intern Med

37. Anonymous. Neoadjuvant hormonal therapy with flutamide for prostate cancer. (MedLettDrgTher 1997, in press).
38. Garnick MB. Prostate cancer. In World Book Encyclopedia. Chicago: World Book Publishing. 1997.
39. Garnick MB. Medicine. In World Book Encyclopedia. Chicago: World Book Publishing. 1998.
40. Anonymous. Nilutamide for prostate cancer. (Med Lett Drug Ther 1997,
41. Garnick MB. Prostate Cancer, in World Book Encyclopedia. Chicago: World Book Publishing, 2001
42. Garnick, MB Cancer, in World Book Encyclopedia. Chicago, World Book Publishing. (in press)

Chapters in Books

1. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III. Preclinical rationale and phase I clinical trials of an adriamycin analog, AD 32. In: Carter SK, Sakurai Y, Umezawa H, eds. Recent results in cancer research, new drugs in cancer chemotherapy. New York: Springer Verlag, 1981:7-15.
2. Goslin RH, Garnick MB. Metoclopramide as an antiemetic in patients receiving Cisplatin. In: Poster DS, Penta JS, Bruno S, eds. Treatment of cancer chemotherapy-induced nausea and vomiting. New York: Masson, 1981:159-165.
3. Dowd JB, Scully RE, Weber ET, Garnick MB. Cancer of the testicle. In: Cancer: a manual for practitioners. 6th ed. Boston: American Cancer Society Massachusetts Division, Inc., 1982:251-259.
4. Garnick MB, Prout GR Jr, Canellos GP. Germinal tumors of the testis. In: Holland JF, Frei E III, eds. Cancer Medicine. 2nd edition. Philadelphia: Lea and Febiger, 1982:1937-1956.
5. Garnick MB, Prout GR Jr, Canellos GP. Cancer of the prostate. In: Holland JF, Frei III, eds. Cancer Medicine. 2nd edition. Philadelphia: Lea and Febiger, 1982:1912-1934.
6. Prout GR Jr, Garnick MB, Canellos GP. The bladder. In: Holland JF, Frei E III, eds. Cancer Medicine. 2nd edition. Philadelphia: Lea and Febiger, 1982:1896-1912.
7. Prout GR Jr, Garnick MB. The kidney and ureter. In: Holland JF, Frei E III, eds. Cancer Medicine. 2nd edition. Philadelphia: Lea and Febiger, 1982:1880-1896.
8. Prout GR Jr, Garnick MB. Carcinoma of the penis. In: Holland JF, Frei E III, eds. Cancer Medicine. 2nd edition. Philadelphia: Lea and Febiger, 1982:1934-1937.
9. Richie JR, Garnick MB. Primary renal and ureteral cancer. In: Rieselbach RE, Garnick MB, eds. Cancer and the Kidney. Philadelphia: Lea and Febiger, 1982:662-706.

10. Boxer RJ, Garnick MB, Anderson T. Extrarenal cancer of the genitourinary tract. In: Rieselbach RE, Garnick MB, eds. *Cancer and the Kidney*. Philadelphia: Lea and Febiger, 1982:718-741.
11. Abelson HT, Garnick MB. Cancer chemotherapy induced renal failure. In: Rieselbach RE, Garnick MB, eds. *Cancer and the Kidney*. Philadelphia: Lea and Febiger, 1982:769-813.
12. Garnick MB, Abelson HT, Mayer RJ. Acute renal failure associated with cancer treatment. In: Brenner BM, Lazarus JM, eds. *Acute Renal Failure*. Philadelphia: W.B. Saunders Co., 1983:527-554.
13. Garnick MB. Management of advanced prostate cancer. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:31-38.
14. Garnick MB, Richie JP. Renal cell carcinoma - diagnostic workup and natural history. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:41-50.
15. Garnick MB, Richie JP. Cancers of the renal pelvis and ureter. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:69-74.
16. Garnick MB. Intravesical chemotherapy for superficial bladder carcinoma. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:101-108.
17. Garnick MB. Assessment of renal function II - cancer chemotherapy induced nephrotoxicity. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:183-196.
18. Garnick MB. Chemotherapy of penile cancer. In: Garnick MB, Richie JP, eds. *Urologic Cancer. A Multidisciplinary Perspective*. New York: Plenum Publishing, 1983:255-256.
19. Rieselbach RE, Garnick MB. Renal complications of cancer. In: Glasscock RJ, ed. *Current Therapy in Nephrology and Hypertension*. Philadelphia: B.C. Decker, Inc., 1984:186-192.
20. Garnick MB, Rieselbach RE. Renal complications of cancer. In: Carbone PP, Brain M, eds. *Current Therapy in Hematology/Oncology*. Philadelphia: B.C. Decker, Inc., 1985:249-254.
21. Garnick MB. Urologic cancer. In: Rubenstein E, Federman DD, eds. *Scientific American Medicine*. Section 12. Volume IX. New York: Scientific American, 1985:1-17.
22. Garnick MB. Gynecologic cancer. In: Rubenstein E, Federman DD, eds. *Scientific American Medicine*. Section 12. Volume X. New York: Scientific American, 1986:1-8.
23. Richie JP, Garnick MB. Tumors of the urinary tract. In: Nealon TF, ed. *Management of the Patient with Cancer*. 3rd edition. Philadelphia: W.B. Saunders Co., 1986:432-453.

24. Garnick MB, Richie JP. Renal neoplasia. In: Brenner BM, Rector FC, Jr., eds. *The Kidney*. 3rd edition. Philadelphia: Ardmore Medical Books, 1986; 11:1533-1550.
25. Robert NJ, Garnick MB, Frei E III. Undifferentiated neoplasms and cancers of unknown primary: a clinicopathological perspective. In: Fer MF, Greco FA, Oldham RK, eds. *Poorly Differentiated Neoplasms and Tumors of Unknown Origin*. Orlando: Grune & Stratton, Inc., 1986:541-554.
26. Sherman ML, Garnick MB. Adenocarcinoma of unknown origin: evaluation and therapy. In: Fer MF, Greco FA, Oldham RK, eds. *Poorly Differentiated Neoplasms and Tumors of Unknown Origin*. Orlando: Grune & Stratton, Inc., 1986:121-152.
27. Mayer RJ, Garnick MB. Cancer of the stomach and small intestine. In: Holleb AI, ed. *The American Cancer Society Book*. New York: Doubleday & Co., 1986:548-554.
28. Mayer RJ, Garnick MB. Liver cancer. In: Holleb AI, ed. *The American Cancer Society Book*. New York: Doubleday & Co., 1986:395-400.
29. Garnick MB, Scully RE, Weber ET, Krane RJ. Cancer of the testis. In: *Cancer: A Manual for Practitioners*. 7th edition. Boston: American Cancer Society, Massachusetts Division, Inc., 1986:268-277.
30. Garnick MB. Testicular cancer. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. *Harrison's Principles of Internal Medicine*. 11th edition. New York: McGraw-Hill Book Company, 1987:1578-1581.
31. Garnick MB, Brenner BM. Tumors of the urinary tract. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JB, Fauci AS, eds. *Harrison's Principles of Internal Medicine*. 11th edition. New York: McGraw-Hill Book Company, 1987:1218-1221.
32. Friedman EL, Garnick MB. Extragonadal germ cell tumors: new therapeutic approaches. In: Muggia FM, ed. *Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy*. Boston: Martinus Nijhoff Publishers, 1987:103-128.
33. Garnick MB, Lipton A, Harvey A, Max DT, Smith JA, Glode LM. LHRH Trials with leuprolide In: Vickery BH, Nestor JJ Jr, eds. *LHRH and its Analogs. Contraceptive and Therapeutic Applications. Part 2*. Boston: MTP Press Limited, 1987:384-395.
34. Garnick MB, Rieselbach RE. Renal complications of cancer. In: Bayless TM, Brain MC, Cherniack RM, eds. *Current Therapy in Internal Medicine - 2*. Toronto: B.C. Decker Inc., 1987:427-432.
35. Rieselbach RE, Garnick MB. Renal diseases induced by antineoplastic agents. In: Schrier RW, Gottschalk CW, eds. *Diseases of the Kidney*. 4th edition. Volume 2. Boston: Little Brown and Company, 1988:1275-1299.
36. Garnick MB, Swanson LJ, Max DT. A randomized prospective evaluation of leuprolide versus diethylstilbestrol in the treatment of stage D2 metastatic prostate cancer: results of a multicenter study. In: Coffey DS, Resnick MI, Dorr FA, Karr JP, eds. *A multidisciplinary analysis of controversies in the management of prostate cancer*. New York: Plenum Publishing, 1988:233-243.

37. Resnick MI, Bagshaw MA, Dorr FA, Garnick MB, Horton J, Prout GR Jr, Scardino PT, Stamey TA. Response/Progression Criteria for Evaluating Prostate Cancer. In: Coffey DS, Resnick MI, Dorr FA, Karr JP, eds. A multidisciplinary analysis of controversies in the management of prostate cancer. New York: Plenum Publishing, 1988:299-308.
38. Garnick MB, Richie JP. Primary neoplasms of the kidney and renal pelvis. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 4th edition. Volume 1. Boston: Little Brown and Company. 1988:863-892.
39. Young D, Garnick MB. Chemotherapy in bladder cancer: the North American experience. In: Raghavan D, ed. The Management of Bladder Cancer. London: Edward Arnold, 1988:245-263.
40. Garnick MB, Mayer RJ, Abelson HT. Acute renal failure associated with cancer treatment. In: Brenner BM, Lazarus JM, eds. Acute Renal Failure. 2nd edition. Philadelphia: W.B. Saunders, 1988:621-657.
41. Brodsky GL, Garnick MB. Renal tumors in the adult patient. In: Tisher CC, Brenner BM, eds. Renal Pathology with Clinical and Functional Correlations. Volume II. Philadelphia: J.B. Lippincott, 1989:1467-1504.
42. Weber B, Garnick MB, Rieselbach RE. Nephropathies due to antineoplastic agents. In: Massry SG, Glasscock RJ, eds. Textbook of Nephrology, 2nd edition. Volume 1. Baltimore: Williams & Wilkins, 1989:818-822.
43. Garnick MB. Management of metastatic carcinoma of the prostate - treatment options and controversies. In: Paulson DF, ed. Prostatic Disorders. Philadelphia: Lea & Febiger, 1989:354-367.
44. Garnick MB, O'Reilly RJ. Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6. In: Golde DW, ed. Hematology/Oncology Clinics of North America. Volume 3. Philadelphia: W.B. Saunders, 1989:495-509.
45. Garnick MB, Krane RJ, Scully RE, Weber ET. Cancer of the testis. In: Osteen RT, ed. Cancer: A Manual for Practitioners, 8th edition. Boston: American Cancer Society Massachusetts Division, Inc. 1990: 304-314.
46. Garnick MB. Testicular cancer. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's Principles of Internal Medicine. 12th edition. New York: McGraw-Hill Book Company. 1991:1625-1629.
47. Garnick MB, Brenner BM. Tumors of the urinary tract. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's Principles of Internal Medicine. 12th edition. New York: McGraw-Hill Book Company. 1991:1625-1629.
48. Garnick MB. Cancer of the genitourinary tract. In: Skarin AT, ed. Atlas of Diagnostic Oncology. Philadelphia: J.B. Lippincott. 1991:4.2-4.41.
49. Garnick MB. Hematopoietic growth factors. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams and Wilkins, 1992:96-109.

50. Crosier PS, Garnick MB, Clark SC. In: Aggarwal BB, Gutterman JU, eds. Human Cytokines: Handbook for Basic and Clinical Research. Cambridge: Blackwell Scientific Publications, 1992:238-252.
51. Garnick MB, Abels R, Rudnick SA. The role of recombinant human erythropoietin in the management of anemia associated with acquired immunodeficiency syndrome. In: Gurland HJ, Moran J, Samtleben W, Scigalla P, Wiecezorek L., eds. Erythropoietin in Renal and Non-Renal Anemias. Update on Basic Research and Clinical Applications. Contributions to Nephrology. Volume 88. Proceedings of the 3rd International Workshop on Treatment of Anemia with Recombinant Human Erythropoietin, Telfs-Buchen, June 7-10, 1990. Basel: Karger, 1991:282-292.
52. Garnick MB. Urologic complications. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine. 3rd edition. Philadelphia: Lea and Febiger. 1993:2323-2331.
53. VandePol CJ, Garnick MB. Clinical applications of recombinant macrophage-colony stimulating factor (rhM-CSF). In: Herrmann F, Mertelsmann R, eds. Biotechnology Therapeutics. Special Issue on Growth Factors. Volume 2, Numbers 3 and 4. New York: Marcel Dekker, Inc., 1991:231-239.
54. Garnick MB, Richie JP. Renal neoplasia. In: Brenner BM, Rector FC, Jr., eds. The Kidney. 4th edition. Philadelphia: W.B. Saunders. 1991:1809-1827.
55. Garnick MB. Superficial bladder carcinoma. In: Waxman J, Williams G, eds. Urological Cancer: A Consensus. Edward Arnold (In press).
56. Garnick MB, Hayes DF. Oncology (Case Study). In: Braunwald E, Rose BD, eds. Intensive Review of Internal Medicine. 4th edition. Boston: The Nimrod Press, 1993:561-572.
57. Rieselbach RE, Garnick MB. Renal diseases induced by antineoplastic agents. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 5th edition. Boston: Little, Brown and Company, 1993:1165-1186.
58. Garnick MB, Richie JP. Primary neoplasms of the kidney and renal pelvis. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 5th edition. Boston: Little, Brown and Company, 1993:785-809.
59. Garnick MB. Testicular cancer and other trophoblastic diseases. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. 13th edition. New York: McGraw-Hill Book Company. 1994:1858-1862.
60. Garnick MB, Brenner BM. Tumors of the urinary tract. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. 13th edition. New York: McGraw-Hill Book Company. 1994:1336-1339.
61. Brodsky GL, Garnick MB. Renal tumors in the adult patient. In: Tisher CC, Brenner BM, eds. Renal Pathology with Clinical and Functional Correlations. 2nd edition. Philadelphia: J.B. Lippincott. 1994:1540-1577.

62. Garnick MB. Renal and urologic complications of cancer and its treatment. In: Greenberg A, ed. NKF Nephrology Primer. San Diego: Academic Press, Inc. 1994:222-226.
63. Garnick MB. Renal and metabolic complications. In: Kirkwood JM, Lotze MT, Yasko JM, eds. Current Cancer Therapeutics. Philadelphia: Current Medicine. 1994:264-271.
64. Sherman ML, Stein EA, Isaacsohn J, Lees RS, Garnick MB. Role of recombinant human macrophage colony-stimulating factor (rhM-CSF) in cholesterol metabolism and atherosclerosis. In Woodford FP, Davignon J, and Sniderman A, eds. Atherosclerosis X. Elsevier Science B.V. 598-602, 1995.
65. Garnick MB, Richie JP. Renal neoplasia. In: Brenner BM, Rector FC Jr, eds. The Kidney. 5th edition. Orlando: WB Saunders Company, 1996;pp. 1959-1977.
66. McDougal WS, Garnick MB. Clinical signs and symptoms of renal cell carcinoma. In Comprehensive textbook of genitourinary oncology. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Williams and Wilkins, Baltimore. 1996: Chapter 9 154-159.
67. Shapiro CL, Garnick MB, Kantoff PW. Tumors of the Kidney, Ureter, and Bladder. In Cecil's Textbook of Medicine, 20th Edition. Bennett, CJ and Plum, F. eds. WB Saunders Company . 1996;pp 623-626.
68. Garnick MB, Krane RJ, Scully RE, Weber ET. Cancer of the testis. In: Osteen RT, ed. Cancer: A Manual for Practitioners, 9th edition. Boston: American Cancer Society Massachusetts Division, Inc. 1997 (in press).
69. Garnick MB. Prostate cancer. In: Dale D, Federman DD, eds. Scientific American Medicine. New York: Scientific American, 1995: IXA: 1-11.
70. Garnick, MB. Gynecologic Cancer. In: Dale D, Federman DD, eds. Scientific American Medicine. New York: Scientific American, 1995: X: 1-14.
71. Garnick, MB. Renal and Urologic Complications of Cancer and Its Treatment. In Greenberg, A, ed. Primer on Kidney Diseases. San Diego: Academic Press and National Kidney Foundation 1994: 222-226.
72. Garnick MB, Richie JP. Primary neoplasms of the kidney and renal pelvis. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 6th edition. Boston: Little, Brown and Company, 1995 (In Press).
73. Rieselbach RE, and Garnick, M. Nephropathies caused by antineoplastic agents. In: Massry SG, Glasscock RJ, eds. Textbook of Nephrology, 3rd edition. Volume 1. Baltimore: Williams & Wilkins, 1995:935-940.
74. Garnick, MB. Renal and Urologic Complications of Cancer and Its Treatment. In Greenberg, A, ed. Primer on Kidney Diseases. San Diego: Academic Press and National Kidney Foundation (In press, 1996).
75. Garnick, MB. Bladder, renal and testicular cancer. In: Dale D, Federman DD, eds. Scientific American Medicine. New York: Scientific American, 1995: IXB: 1-12.

76. Garnick MB et al. Observation (for Early Stage Prostate Cancer) in Guide to Prostate Cancer. Kantoff P, Wishnow K, and Loughlin K, eds. Blackwell Science, Inc. Cambridge Mass. 1996, 72-97.
77. Corliss C, Kantoff P, Garnick MB. Cancer of the genitourinary tract. In: Skarin AT, ed. Atlas of Diagnostic Oncology. (2nd ed) Philadelphia: Mosby-Wolfe. 1996 (in press)
78. Herman, ML, Garnick MB . Hematopoietic growth factors. In: Perry MC, ed. The Chemotherapy Source Book. (2nd ed.) Baltimore: Williams and Wilkins, 1996, pp. 141-154.
79. Garnick MB, Richie JP. Primary neoplasms of the kidney and renal pelvis. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 6th edition. Boston: Little, Brown and Company, 1996.
80. Garnick MB. Primary neoplasms of the kidney. In Brenner B, Brady HR, and Wilcox CS. Therapy in nephrology and hypertension. Orlando. WB Saunders Co. 1997.
81. Stoudemire JB, Garnick MB. The clinical promise of recombinant human macrophage colony stimulating factor (rhM-CSF). In: Peters WP, ed. Hematopoietic Growth Factors New York: Futura Press, 1997.
82. Schaub RG, Sypek JP, Keith JC, Munn DH, Sherman ML, Dorner AJ, Garnick MB. Macrophage Colony Stimulating Factor. International Handbook of Immunopharmacology: Cytokines. 1997.
83. Garnick, MB. Renal and urologic complications of cancer and its treatment. In Greenburg, A., ed. Primer on Kidney Diseases (2nd ed) Academic Press, 1996.
84. Garnick, MB. Medicine. World Book Encyclopedia. Volume 13; 363-379. World Book Publishing, Chicago, 1999.
85. Garnick MB. Respirator. World Book Encyclopedia. Chicago: World Book Publishing 2005 (print edition): 261-2 (R)
86. Garnick MB. Rheumatism. World Book Encyclopedia. Chicago: World Book Publishing 2005 (print edition): 291 (R)
87. Garnick MB. Tabes. World Book Encyclopedia. Chicago: World Book Publishing 2005 (print edition): 2(T)

Textbooks and Monographs

1. Rieselbach RE, Garnick MB, eds. and authors. Cancer and the kidney. Philadelphia: Lea and Febiger, 1982. (Textbook)
2. Garnick MB, Richie JP, eds. and authors. Urologic cancer. A multidisciplinary perspective. New York: Plenum Publishing, 1983. (Textbook)
3. Garnick MB, ed. Genitourinary cancer. Contemporary issues in clinical oncology. Volume 5. New York: Churchill Livingstone, 1985. (Textbook)
4. Garnick MB. Carcinoma of the bladder. Insights into cancer therapeutics. Philadelphia: Meniscus Limited, 1985. (Monograph)
5. Garnick MB, ed. Contemporary Issues in Urologic Cancer. Seminars in Oncology. Volume 4. 1988. (Monograph)
6. Garnick MB. Chemotherapy in advanced prostate cancer. In: Wein A, Malkowicz SB, eds. Cancer of the prostate: current practice and future directions. Part III. Philadelphia: CoMed Communications, 1989:30-39. (Monograph)
7. Garnick MB, ed. Erythropoietin: pharmacology and clinical applications. New York: Marcel Dekker, Inc., 1990. (Textbook)
8. Garnick MB, ed. Seminars in Oncology. Hematopoietic Growth Factors. Volume 19, 1992. (Monograph)
9. Garnick, MB: Prostate Cancer: The patient's guide to prostate cancer: An expert's successful treatment strategies and options. Dutton Signet Books, 1996.(Popular book)
10. Fair WR, Garnick MB. Guest Editors. The first international conference on neoadjuvant hormonal therapy for prostate cancer. Boston, March 28, 29, 1996. Urology 1997;49 (suppl 3A)1-123. (Monograph)
11. Garnick MB, Fair,WR. Guest Editors. The second international conference on neoadjuvant hormonal therapy for prostate cancer. Boston, March 14 and 15, 1997. Molecular Urology (1997, In press). (Monograph)
12. Garnick MB, Fair, WR. Guest Editors. The third international conference on neoadjuvant hormonal therapy for prostate cancer. Boston March 13 and 14, 1998. Molecular Urology, need date and volume (Monograph)
13. Garnick MB, Fair, WR. Guest Editors. The fourth international conference on neoadjuvant hormonal therapy for prostate cancer. Boston March 13 and 14, 1998. Molecular Urology, need date and volume (Monograph)

Non-Print Materials

1. Garnick MB. Urologic Cancer. Scientific American Medicine on CD-ROM. 1988-1996
2. Garnick MB. Gynecologic Cancer. Scientific American Medicine on CD-ROM. 1988-1997
3. Fair WR, Murphy WM, Garnick MB, Goldenberg SL, McLeod DG, Soloway MS. Neoadjuvant therapy before prostatectomy. Educational video for physician education. 1997
4. Garnick MB. Prostate Cancer. Scientific American Medicine on CD-ROM. 1996-Present.
5. Garnick MB. Renal, Testis and Bladder Cancers. Scientific American Medicine on CD-ROM. 1996-Present
6. Garnick MB. Prostate Cancer. UpToDate in Medicine on CD-ROM. 1997;4(No.1), 1996
7. Garnick MB (contributor). Shared Decision Resource for Prostate Cancer Patients. Shared Decisions on CD-ROM. 1997
8. Garnick MB. Prostate cancer. In World Book Encyclopedia. Chicago: World Book Publishing. Multimedia CD-ROM 1997
9. Garnick MB. Colo-rectal cancer. In World Book Encyclopedia. Chicago: World Book Publishing. Multimedia CD-ROM 1997
10. Garnick MB. Medicine. In World Book Encyclopedia. Chicago: World Book Publishing. Multimedia CD-ROM 1997

Editorial Comments

1. Garnick MB. Advanced testicular cancer: treatment choices in the "land of plenty." [Editorial] J Clin Oncol 1985;3:294-297.
2. Garnick MB, Richie JP. Toward a more rational approach for stage I testis cancer: Watch out for
3. Garnick MB. Editorial Comment on Hormonal Management of Stage D Carcinoma of the Prostate. Urologic Clinics of North America. 1987;14:693-694.
4. Kantoff PW, Garnick MB. Late toxicities, long-term follow-up, less intensive treatment: leading issues in the therapy of testis cancer. [Editorial] J Clin Oncol 1988;6:1216-1219.
5. Garnick MB. Current issues in urologic cancer. [Editorial] Seminars in Oncology 1988;4:319-320.
6. Garnick MB. Chemotherapy and bladder cancer. [Editorial] J Urol 1989;141:107.

7. Garnick MB. Editorial Comment regarding: Belldegrin A, Webb DE, Austin HA, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of Interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. *J Urol* 1989;141:499.
8. Garnick MB. Editorial Comment regarding: Galetti TP, Pontes JE, et al. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: results and follow-up. *J Urol* 1989;142:1214-1215.
9. Garnick MB. Editorial Comment regarding: Moul JW, Robertson JE, George SL, Paulson DF. Complications of therapy for testicular cancer. *J Urol* 1989.
10. Garnick MB. Editorial Comment regarding: Glaspy JA, Golde DW. G-CSF and GM-CSF can help prevent chemo-induced neutropenia and treat cytopenias associated with myelodysplastic syndromes and aplastic anemia. *Oncology* 1990;4:32.
11. Garnick MB. Editorial Comment regarding: See WA, Williams RD. Tumors of the urinary tract. *Western J Med* 1992;156:556.
12. Garnick MB. Editorial Comment regarding: Prout et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. *J Urol* (In press).
13. Garnick MB. Editorial Comment regarding: Igawa M, Ohkuchi T, Ueda M, Okada K, Usui T. Usefulness and limitations of methotrexate, vinblastine, adriamycin, cisplatin (M-VAC) for the treatment of advanced urothelial cancer. *J Urol* (In press).
14. Garnick MB. Editorial Comment regarding: Fleming C, Wasson JH, Albertson PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. *Abstracts of Clinical Care Guidelines* 1993;5:11.
15. Garnick MB. editorial comment on Flutamide Hepatotoxicity (Wysoski DK Fourcroy JL. Flutamide Hepatotoxicity. *J Urol* 1996;155:209-212) *J Urol*. 1996;155:212.
16. Garnick MB. Are treatment messages reaching our late-stage prostate cancer patients? *Oncology Times* 1995;XVII:2.
17. Garnick MB. A new study reinforces the need for prostate cancer patient/physician communication. *Coping*. 1996;10:36-37.
18. Fair WR and Garnick MB. Neoadjuvant therapy prior to radical prostatectomy: Pro. *Urology* 1996;48:535-538.
19. Garnick MB. Editorial Comment regarding: Israel VK, Russell CA, Dolkar D, Streeter O. Current mediastinal nonseminomatous germ cell malignancy. *The Tumor Board: Cancer Diagnosis and Treatment*. 1994.

Abstracts

1. Garnick, MB, Gaylis, F, Woolley, JM. Abarelix Depot Improves Health-Related Quality of Life in Highly Symptomatic Prostate Cancer Patients.
2. Garnick, MB, Gaylis, F, Woolley, JM. The Relationship Between the Swog 9039 Health-Related Quality of Life Questionnaire and ECOG Performance Scores in Highly Symptomatic Prostate Cancer Patients.
3. Garnick, MB, Gaylis, F, Woolley, JM. Assessment of the Content Validity of the Euroqol EQ-5D Health-Related Quality of Life Questionnaire in Highly Symptomatic Prostate Cancer Patients.
4. Garnick, MB, Gaylis, F, Woolley, JM. The Economic Value of Abarelix Depot Therapy in Highly Symptomatic Prostate Cancer Patients.

Letters

1. Garnick MB. Hot watch syndrome. [Letter] N Engl J Med 1976;294:51.
2. Garnick MB, Mayer RJ, Richie JP. Testicular self-examination. [Letter] N Engl J Med 1980;302:297.
3. Garnick MB. Oral metoclopramide and cisplatin chemotherapy. [Letter] Ann Intern Med 1983;99:127.
4. Garnick MB, Ernst T, Martinez F. Acute febrile reaction to streptozotocin. [Letter] N Engl J Med 1984;311:798.
5. Garnick MB. Case Record #48-1987: pulmonary mass of 3 1/2 years' duration. [Letter] N Engl J Med 1988; 318:1467.
6. Talcott JA, Garnick MB, Stomper PC, Godleski JJ, Richie JP. Nodular pneumonitis after cancer chemotherapy. [Letter] Ann Intern Med 1989;110:91.

Book Reviews

1. Garnick MB. Review of Tannock IF, Hill RP, eds. The basic science of oncology. Elmsford, New York: Pergamon Press, 1987. In: N Engl J Med 1987;317:459.
2. Garnick MB, Canellos GP. Review of Magrath IT, ed. The non-Hodgkin's lymphomas. Baltimore, Williams and Wilkins, 1990. In: N Engl J Med 1990;323:1430.

3. Garnick MB. Review of Broder S, ed. Molecular foundations of oncology. Baltimore: Williams and Wilkins, 1991. In: N Engl J Med 1992;326:1297.